Compare CVV & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVV | RNAZ |
|---|---|---|
| Founded | 1982 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.5M | 27.9M |
| IPO Year | 2007 | 2021 |
| Metric | CVV | RNAZ |
|---|---|---|
| Price | $4.28 | $1.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 110.3K | 45.4K |
| Earning Date | 11-09-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.86 | N/A |
| EPS | ★ 1.58 | N/A |
| Revenue | ★ $41,128,639.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.77 | ★ N/A |
| Revenue Growth | ★ 96.27 | N/A |
| 52 Week Low | $2.96 | $1.52 |
| 52 Week High | $9.10 | $20.99 |
| Indicator | CVV | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 28.03 | 39.34 |
| Support Level | $3.79 | $1.58 |
| Resistance Level | $4.90 | $2.39 |
| Average True Range (ATR) | 0.20 | 0.22 |
| MACD | 0.04 | 0.11 |
| Stochastic Oscillator | 36.62 | 28.74 |
CVD Equipment Corp designs, develops, and manufactures a broad range of equipment used to develop and produce materials and coatings for the aerospace, compound semiconductor, semiconductor, aerospace, battery energy storage markets as well as industrial applications, and research. It currently conducts its business through two reportable segments: CVD Equipment, which designs and manufactures chemical vapor deposition, physical vapor transport and thermal process equipment; and SDC, which designs and manufactures ultra-high purity gas and chemical delivery control systems. Its target markets are aerospace & defense and industrial, microelectronics / high power electronics, and EV battery materials / energy storage.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.